nach oben

Journal of Neural Transmission

Erschienen in:

01.02.2016 | Neurology and Preclinical Neurological Studies - Review Article

Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease

verfasst von: Edna Grünblatt, Peter Riederer

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Evidence suggests that aldehyde dehydrogenase (ALDH; E.C. 1.2.1.3) gene, protein expression and activity are substantially decreased in the substantia nigra of patients with Parkinson’s disease (PD). This holds especially true for cytosolic ALDH1A1, while mitochondrial ALDH2 is increased in the putamen of PD. Similarly, in Alzheimer’s disease (AD) several studies in genetic, transcriptomic, protein and animal models suggest ALDH involvement in the neurodegeneration processes. Such data are in line with findings of increased toxic aldehydes, like for example malondialdehyde, nonenal, 3,4-dihydroxyphenylacetaldehyde and others. Genetic, transcriptomic and protein alterations may contribute to such data. Also in vitro and in vivo experimental work points to an important role of ALDH in the pathology of neurodegenerative disorders. Aims at investigating dysfunctions of aldehyde detoxification are suitable to define genetic/molecular targets for new therapeutic strategies balancing amine metabolism in devastating disorders like PD and probably also AD.

Agid Y, Javoy F, Youdim MB (1973) Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6-hydroxydopamine lesion of the nigrostriatal pathway. Br J Pharmacol 48(1):175–178PubMedCentralCrossRefPubMed

Alvarez-Lopez MJ, Castro-Freire M, Cosin-Tomas M, Sanchez-Roige S, Lalanza JF, Del Valle J, Parrizas M, Camins A, Pallas M, Escorihuela RM, Kaliman P (2013) Long-term exercise modulates hippocampal gene expression in senescent female mice. J Alzheimers Dis 33(4):1177–1190. doi:10.3233/JAD-121264 PubMed

Anderson DW, Schray RC, Duester G, Schneider JS (2011) Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system. Brain Res 1408:81–87. doi:10.1016/j.brainres.2011.06.051 PubMedCentralCrossRefPubMed

Bai J, Mei Y (2011) Overexpression of aldehyde dehydrogenase-2 attenuates neurotoxicity induced by 4-hydroxynonenal in cultured primary hippocampal neurons. Neurotox Res 19(3):412–422. doi:10.1007/s12640-010-9183-1 CrossRefPubMed

Black W, Vasiliou V (2009) The aldehyde dehydrogenase gene superfamily resource center. Hum Genomics 4(2):136–142PubMedCentralCrossRefPubMed

Black WJ, Stagos D, Marchitti SA, Nebert DW, Tipton KF, Bairoch A, Vasiliou V (2009) Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. Pharmacogenet Genomics 19(11):893–902. doi:10.1097/FPC.0b013e3283329023 PubMedCentralCrossRefPubMed

Budas GR, Disatnik MH, Chen CH, Mochly-Rosen D (2010) Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKCvarepsilon) knockout mice. J Mol Cell Cardiol 48(4):757–764. doi:10.1016/j.yjmcc.2009.10.030 PubMedCentralCrossRefPubMed

Dedek J, Baumes R, Tien-Duc N, Gomeni R, Korf J (1979) Turnover of free and conjugated (sulphonyloxy) dihydroxyphenylacetic acid and homovanillic acid in rat striatum. J Neurochem 33(3):687–695CrossRefPubMed

Duncan RJ, Sourkes TL, Boucher R, Poirier LJ, Roberge A (1972) Aldehyde dehydrogenase and monoamine oxidase in the striatum of cats with nigrostriatal lesions. J Neurochem 19(8):2007–2010CrossRefPubMed

Durrenberger PF, Grünblatt E, Fernando FS, Monoranu CM, Evans J, Riederer P, Reynolds R, Dexter DT (2012) Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study. Parkinsons Dis 2012:214714. doi:10.1155/2012/214714 PubMedCentralPubMed

Fishman-Jacob T, Youdim MB, Mandel SA (2010) Silencing/overexpressing selected genes as a model of sporadic Parkinson’s disease. Neurodegener Dis 7(1–3):108–111. doi:10.1159/000285517 CrossRefPubMed

Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA, O’Donnell KC, Barnhill L, Casida JE, Cockburn M, Sagasti A, Stahl MC, Maidment NT, Ritz B, Bronstein JM (2013) Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci USA 110(2):636–641. doi:10.1073/pnas.1220399110 PubMedCentralCrossRefPubMed

Fitzmaurice AG, Rhodes SL, Cockburn M, Ritz B, Bronstein JM (2014) Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease. Neurology 82(5):419–426. doi:10.1212/WNL.0000000000000083 PubMedCentralCrossRefPubMed

Galter D, Buervenich S, Carmine A, Anvret M, Olson L (2003) ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson’s disease and in the ventral tegmental area in schizophrenia. Neurobiol Dis 14(3):637–647CrossRefPubMed

Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, Bhatia K, Chen LZ, Fang B, Lisker R et al (1992) Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 88(3):344–346CrossRefPubMed

Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, Sharabi Y (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J Neurochem 126(5):591–603. doi:10.1111/jnc.12345 PubMedCentralCrossRefPubMed

Grünblatt E (2012) Parkinson’s disease: molecular risk factors. Parkinsonism Relat Disord 18(Suppl 1):S45–S48. doi:10.1016/S1353-8020(11)70016-5 CrossRefPubMed

Grünblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111(12):1543–1573CrossRefPubMed

Grünblatt E, Zehetmayer S, Jacob CP, Muller T, Jost WH, Riederer P (2010) Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease. J Neural Transm. doi:10.1007/s00702-010-0509-1

Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, Vasiliou V (2011) Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 5(4):283–303PubMedCentralCrossRefPubMed

Komatsu M, Shibata N, Ohnuma T, Kuerban B, Tomson K, Toda A, Tagata Y, Nakada T, Shimazaki H, Arai H (2014) Polymorphisms in the aldehyde dehydrogenase 2 and dopamine beta hydroxylase genes are not associated with Alzheimer’s disease. J Neural Transm 121(4):427–432. doi:10.1007/s00702-013-1112-z CrossRefPubMed

Kong D, Kotraiah V (2012) Modulation of aldehyde dehydrogenase activity affects (±)-4-hydroxy-2E-nonenal (HNE) toxicity and HNE-protein adduct levels in PC12 cells. J Mol Neurosci 47(3):595–603. doi:10.1007/s12031-011-9688-y CrossRefPubMed

Kotraiah V, Pallares D, Toema D, Kong D, Beausoleil E (2013) Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening. J Enzyme Inhib Med Chem 28(3):489–494. doi:10.3109/14756366.2011.653353 CrossRefPubMed

Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, Kopin IJ (2000) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 60(4):552–558CrossRefPubMed

Larson HN, Weiner H, Hurley TD (2005) Disruption of the coenzyme binding site and dimer interface revealed in the crystal structure of mitochondrial aldehyde dehydrogenase “Asian” variant. J Biol Chem 280(34):30550–30556. doi:10.1074/jbc.M502345200 PubMedCentralCrossRefPubMed

Legros H, Dingeval MG, Janin F, Costentin J, Bonnet JJ (2004) Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology 25(3):365–375. doi:10.1016/S0161-813X(03)00148-7 CrossRefPubMed

Maes OC, Schipper HM, Chertkow HM, Wang E (2009) Methodology for discovery of Alzheimer’s disease blood-based biomarkers. J Gerontol A Biol Sci Med Sci 64(6):636–645. doi:10.1093/gerona/glp045 CrossRefPubMed

Mandel SA, Fishman T, Youdim MB (2007) Gene and protein signatures in sporadic Parkinson’s disease and a novel genetic model of PD. Parkinsonism Relat Disord 13(Suppl 3):S242–S247. doi:10.1016/S1353-8020(08)70009-9 CrossRefPubMed

Mandel SA, Fishman-Jacob T, Youdim MB (2012) Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S177–S179. doi:10.1016/S1353-8020(11)70055-4 CrossRefPubMed

Marchitti SA, Brocker C, Stagos D, Vasiliou V (2008) Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4(6):697–720. doi:10.1517/17425255.4.6.697 PubMedCentralCrossRefPubMed

Maring JA, Deitrich RA, Little R (1985) Partial purification and properties of human brain aldehyde dehydrogenases. J Neurochem 45(6):1903–1910CrossRefPubMed

Meyer MJ, Mosely DE, Amarnath V, Picklo MJ Sr (2004) Metabolism of 4-hydroxy-trans-2-nonenal by central nervous system mitochondria is dependent on age and NAD+ availability. Chem Res Toxicol 17(9):1272–1279. doi:10.1021/tx049843k CrossRefPubMed

Michel TM, Gsell W, Kasbauer L, Tatschner T, Sheldrick AJ, Neuner I, Schneider F, Grünblatt E, Riederer P (2010) Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) in the putamen of individuals with Alzheimer’s disease: a human postmortem study. J Alzheimers Dis 19(4):1295–1301. doi:10.3233/JAD-2010-1326 PubMed

Michel TM, Kasbauer L, Gsell W, Jecel J, Sheldrick AJ, Cortese M, Nickl-Jockschat T, Grünblatt E, Riederer P (2014) Aldehyde dehydrogenase 2 in sporadic Parkinson’s disease. Parkinsonism Relat Disord 20(Suppl 1):S68–S72. doi:10.1016/S1353-8020(13)70018-X CrossRefPubMed

Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, Grünblatt E, Riederer P, Jacob C, Aharon-Peretz J, Bashenko Y, Youdim MB, Mandel SA (2012) A molecular signature in blood identifies early Parkinson’s disease. Mol Neurodegener 7:26. doi:10.1186/1750-1326-7-26 PubMedCentralCrossRefPubMed

Ohsawa I, Nishimaki K, Yasuda C, Kamino K, Ohta S (2003) Deficiency in a mitochondrial aldehyde dehydrogenase increases vulnerability to oxidative stress in PC12 cells. J Neurochem 84(5):1110–1117CrossRefPubMed

Ohsawa I, Nishimaki K, Murakami Y, Suzuki Y, Ishikawa M, Ohta S (2008) Age-dependent neurodegeneration accompanying memory loss in transgenic mice defective in mitochondrial aldehyde dehydrogenase 2 activity. J Neurosci 28(24):6239–6249. doi:10.1523/JNEUROSCI.4956-07.2008 CrossRefPubMed

Ohta S, Ohsawa I (2006) Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer’s disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. J Alzheimers Dis 9(2):155–166PubMed

Picklo MJ, Olson SJ, Markesbery WR, Montine TJ (2001) Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. J Neuropathol Exp Neurol 60(7):686–695CrossRefPubMed

Ryzlak MT, Pietruszko R (1987) Purification and characterization of aldehyde dehydrogenase from human brain. Arch Biochem Biophys 255(2):409–418CrossRefPubMed

Rzhetsky A, Ayala FJ, Hsu LC, Chang C, Yoshida A (1997) Exon/intron structure of aldehyde dehydrogenase genes supports the “introns-late” theory. Proc Natl Acad Sci USA 94(13):6820–6825PubMedCentralCrossRefPubMed

Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR (2007) Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc Natl Acad Sci USA 104(3):955–960. doi:10.1073/pnas.0610204104 PubMedCentralCrossRefPubMed

Serrano-Pozo A, Gomez-Isla T, Growdon JH, Frosch MP, Hyman BT (2013) A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol 182(6):2332–2344. doi:10.1016/j.ajpath.2013.02.031 PubMedCentralCrossRefPubMed

Shoeb M, Ansari NH, Srivastava SK, Ramana KV (2014) 4-hydroxynonenal in the pathogenesis and progression of human diseases. Curr Med Chem 21(2):230–237PubMedCentralCrossRefPubMed

Solito R, Corti F, Chen CH, Mochly-Rosen D, Giachetti A, Ziche M, Donnini S (2013) Mitochondrial aldehyde dehydrogenase-2 activation prevents beta-amyloid-induced endothelial cell dysfunction and restores angiogenesis. J Cell Sci 126(Pt 9):1952–1961. doi:10.1242/jcs.117184 PubMedCentralCrossRefPubMed

Song BJ, Abdelmegeed MA, Yoo SH, Kim BJ, Jo SA, Jo I, Moon KH (2011) Post-translational modifications of mitochondrial aldehyde dehydrogenase and biomedical implications. J Proteomics 74(12):2691–2702. doi:10.1016/j.jprot.2011.05.013 PubMedCentralCrossRefPubMed

Stewart MJ, Malek K, Crabb DW (1996) Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues. J Investig Med 44(2):42–46PubMed

Stott SR, Barker RA (2014) Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson’s disease. Eur J Neurosci 39(6):1042–1056. doi:10.1111/ejn.12459 CrossRefPubMed

Strickland KC, Holmes RS, Oleinik NV, Krupenko NI, Krupenko SA (2011) Phylogeny and evolution of aldehyde dehydrogenase-homologous folate enzymes. Chem Biol Interact 191(1–3):122–128. doi:10.1016/j.cbi.2010.12.025 PubMedCentralCrossRefPubMed

Tanzi RE, Bertram L (2001) New frontiers in Alzheimer’s disease genetics. Neuron 32(2):181–184CrossRefPubMed

Vasiliou V, Pappa A, Estey T (2004) Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev 36(2):279–299. doi:10.1081/DMR-120034001 CrossRefPubMed

Werner CJ, Heyny-von Haussen R, Mall G, Wolf S (2008) Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci 6:8. doi:10.1186/1477-5956-6-8 PubMedCentralCrossRefPubMed

Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson’s disease. PLoS One 7(2):e31522. doi:10.1371/journal.pone.0031522 PubMedCentralCrossRefPubMed

Wood PL, Khan MA, Moskal JR (2007) The concept of “aldehyde load” in neurodegenerative mechanisms: cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line. Brain Res 1145:150–156. doi:10.1016/j.brainres.2006.10.004 CrossRefPubMed

Yoshida A, Huang IY, Ikawa M (1984) Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci USA 81(1):258–261PubMedCentralCrossRefPubMed

Yoval-Sanchez B, Rodriguez-Zavala JS (2012) Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts. Chem Res Toxicol 25(3):722–729. doi:10.1021/tx2005184 CrossRefPubMed

Zhang M, Shoeb M, Goswamy J, Liu P, Xiao TL, Hogan D, Campbell GA, Ansari NH (2010) Overexpression of aldehyde dehydrogenase 1A1 reduces oxidation-induced toxicity in SH-SY5Y neuroblastoma cells. J Neurosci Res 88(3):686–694. doi:10.1002/jnr.22230 PubMed

Titel: Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease
verfasst von: Edna Grünblatt
Peter Riederer
Publikationsdatum: 01.02.2016
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 2/2016
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-014-1320-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Mitochondrial mechanisms of redox cycling agents implicated in Parkinson’s disease

Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets

Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease: a brief overview

Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression